News
Press Releases
SolasCure Selected for Innovate UK Global Incubator Programme in Houston
Cambridge, UK 03 June 2024: SOLASCURE Ltd (SolasCure), a biotechnology company developing a novel treatment to transform chronic wound care, today announced it has been
SolasCure Awarded £405K Innovate UK Biomedical Catalyst Grant to Advance Chronic Wound Care
Cambridge, UK 19 March 2024: SOLASCURE Ltd (SolasCure), a biotechnology company developing a novel treatment to transform chronic wound care, today announced it has been
SolasCure Publishes Phase IIa Clinical Trial Report in Leading Wound Care Journal
Cambridge, UK 04 March 2024: SOLASCURE Ltd (SolasCure), a biotechnology company developing a novel treatment to transform chronic wound care, has today announced the publication
SolasCure demonstrates proof-of-concept in Phase lla safety trial of Aurase Wound Gel
Cambridge, UK 12th December 2023: SOLASCURE Ltd (SolasCure), a biotechnology company developing a hydrogel containing tarumase (provisional INN), a recombinant enzyme derived from maggots, and
SolasCure Awarded Prestigious European Innovation Council’s Accelerator Grant
SolasCure, a Cambridge-based biotech company committed to addressing the pressing issue of inadequate debridement solutions for chronic wounds, has been selected to receive European Innovation
SolasCure announces final closing of GBP 10.9m (c. USD 13.3m) Series B fundraise to advance wound care innovation
Funding will support the development of Aurase Wound Gel and progress towardfurther Phase II clinical trials of innovative wound debriding enzyme Cambridge, UK 27 March
SolasCure named a UK Life Sciences Innovator 2023 by the UK’s Department for International Trade
SolasCure, a Cambridge-based biotech company developing revolutionary wound-cleaningtechnology, has been named a UK Life Sciences Innovator in a showcase sponsored by the UK’sDepartment for International Trade.
SolasCure announces publication of toxicology and pre-clinical research programme as final patient is enrolled into pivotal clinical trial
Innovative Cambridge biotech company SolasCure, which is developing a revolutionarywound cleaning technology, has published its pre-clinical results with the InternationalWound Journal, showing preliminary evidence that
SolasCure’s David Fairlamb recognised at TOPRA Awards for exceptional leadership in regulatory strategy
David Fairlamb, Director of Regulatory Affairs at SolasCure, has been named as a winner at the TOPRA awards. The awards, organised by The Organisation for
SolasCure wins 1st place at prestigious EIT Health Catapult biotech competition for investigational wound care product Aurase Wound Gel
SolasCure has been named the winner of the biotech category at the EIT Health Catapult finals in Stockholm. The medical use of Aurase Wound Gel
Cambridge biotech company earns international recognition as first trial patient receives treatment
SolasCure, a Cambridge-based biotech company developing revolutionary wound-cleaning technology, has seen its first trial patient receive treatment. Leveraging biomimicry and evidence-based medicine, the pioneering biologics
Biotech start-up SolasCure has begun clinical trials of its investigational wound cleaning product, Aurase Wound Gel
Cambridge-based biologics company SolasCure has received authorisation to conduct clinical trials for its investigational product, Aurase Wound Gel, from the UK’s Medical and Healthcare products
SolasCure announces £15m Series A raise
Biotech start-up SolasCure has announced the completion of its Series A investment round, to support the development of its wound cleaning product, Aurase. The Cambridge
Blogs
Wound Care Voices: Why the Battle Against Chronic Wounds is Worth Fighting
You need a good reason to be in wound care. Speak to any life sciences investor and they will list the challenges: heterogeneous disease, difficult
Wound Bed Preparation: Addressing the Urgent Need for Effective Solutions
Chronic wounds are suffered by ~100 million people around the world and are an urgent issue lacking effective solutions. While hospitals and specialised clinics often
Harnessing the power of maggots: Cambridge biologics company SolasCure is developing an accessible method for cleaning chronic wounds, inspired by nature’s solution
Maggot therapy, the unpleasant practice of introducing living fly larvae into wounds to remove dead and dying tissue, is astonishingly effective. Its popularity can be
Treating Chronic Wounds Effectively: The Unmet Need
After more than 20 years in the life sciences industry, Dr. Sam Bakri, Executive Chairman and CEO of biotech start-up, SolasCure shares his journey as
European Innovation Council Accelerator: strong performance of engineering and tech-based companies in the latest €350 million funding round
A new set of 47 companies have been selected to receive European Innovation Council (EIC) funding, combining grants and equity, following the third 2023 EIC Accelerator cut-off in June.
30 OCTOBER 2023
EIT Health Catapult 2022 names SolasCure biotech winner
This year’s EIT Health Catapult competition has crowned Cambridge-based start-up SolasCure as champions in the biotech category. Catapult is a pitching competition run by EIT
6 JUNE 2023
SolasCure raises €12M in Series B finance
An EIT Health-supported start-up, SolasCure, has closed a Series B funding round to the value of €12M.
27 APRIL 2023
Seneca Partners invests £1.2m into biotech start-up SolasCure
18 AUGUST 2021
The Biomimicry Institute's AskNature: Improved Wound Debridement Using Maggot Enzymes
Aurase is an investigational product containing maggot enzymes that aims to help remove dead…
11 AUGUST 2021
6 Ireland-UK start-ups ready for the Catapult Semifinals
24 JUNE 2021
A Truly Revolting Treatment Is Having a Renaissance
2 JUNE 2021
Startup Solascure chosen for the URGO Mentorship Program
URGO Group announces the winner of its 2019 URGO Mentorship Program: SolasCure, a Wales-based biotech…
09 SEPTEMBER 2019
BRAIN Biotech AG announces the creation of SolasCure Ltd. to continue development of Aurase
22 AUGUST 2018
BRAIN AG announces the creation of SolasCure Ltd. to continue development of Aurase®
BRAIN is providing IP and fully integrating their development programme for biological wound care based on the Aurase® enzyme…
Startup Solascure chosen for the URGO Mentorship Program
URGO Group announces the winner of its 2019 URGO Mentorship Program: SolasCure, a Wales-based biotech which has developed an innovative wound care solution…
